Andreas L. Marzinzik
Basel, BS, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
Identification and characterization of binders to a cryptic and functional pocket in KRAS.
Journal: Nature communications
Published: October 29, 2024
Quantitative and functional characterisation of extracellular vesicles after passive loading with hydrophobic or cholesterol-tagged small molecules.
Journal: Journal of controlled release : official journal of the Controlled Release Society
Published: March 27, 2023
Biochemical and Structural Characterization of a Peptidic Inhibitor of the YAP:TEAD Interaction That Binds to the α-Helix Pocket on TEAD.
Journal: ACS chemical biology
Published: February 24, 2023
Discovery, X-ray structure and CPP-conjugation enabled uptake of p53/MDM2 macrocyclic peptide inhibitors.
Journal: RSC chemical biology
Published: March 16, 2021
Identification of a PCSK9-LDLR disruptor peptide with in vivo function.
Journal: Cell chemical biology
Published: January 25, 2021
Fragment-Based Discovery of Non-bisphosphonate Binders of Trypanosoma brucei Farnesyl Pyrophosphate Synthase.
Journal: Chembiochem : a European journal of chemical biology
Published: April 21, 2020
Discovery of Potent and Selective Antibody-Drug Conjugates with Eg5 Inhibitors through Linker and Payload Optimization.
Journal: ACS medicinal chemistry letters
Published: October 10, 2019
Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1.
Journal: Journal of medicinal chemistry
Published: August 24, 2018
A segmented flow platform for on-demand medicinal chemistry and compound synthesis in oscillating droplets.
Journal: Chemical communications (Cambridge, England)
Published: June 07, 2017
Bioorthogonal Probes for the Study of MDM2-p53 Inhibitors in Cells and Development of High-Content Screening Assays for Drug Discovery.
Journal: Angewandte Chemie (International ed. in English)
Published: September 01, 2016
The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.
Journal: Nature
Published: February 09, 2016
A General Strategy for Targeting Drugs to Bone.
Journal: Angewandte Chemie (International ed. in English)
Published: July 30, 2015
Last Updated: 09/26/2026